Molecular Imaging and Biology最新文献

{"title":"In Vivo Tracking Modalities for Oncolytic Reovirus: Principles, Clinical Applications, and Translational Integration.","authors":"Malihe Rastegarpanah, Zahra Ziafati Kafi, Babak Negahdari","doi":"10.1007/s11307-026-02092-x","DOIUrl":"10.1007/s11307-026-02092-x","url":null,"abstract":"<p><strong>Objectives: </strong>Oncolytic reovirus, particularly Pelareorep, is a promising cancer therapeutic due to selective replication in Ras-activated tumor cells and immunomodulatory effects. This review aims to critically evaluate current and emerging in vivo tracking strategies, emphasizing translational relevance and clinical implementation.</p><p><strong>Evidence acquisition: </strong>We systematically analyzed preclinical and clinical studies employing optical imaging, nuclear imaging, magnetic resonance imaging, ultrasound/photoacoustic techniques, molecular reporters, and nanoparticle-based platforms. Special focus was placed on integrating functional imaging and molecular assays in Pelareorep trials to monitor viral distribution and therapeutic response.</p><p><strong>Results: </strong>Optical imaging offers high sensitivity for preclinical investigations; however, it is limited by shallow tissue penetration. Nuclear imaging provides quantitative, whole-body monitoring that is suitable for clinical translation, whereas MRI and ultrasound/photoacoustic modalities enable real-time visualization of both structural and functional aspects. Nanotechnology-based platforms facilitate multimodal imaging and targeted delivery, while molecular tools such as reporter genes, CRISPR-driven circuits, and viral barcoding further enhance spatiotemporal resolution. Clinical trials with Pelareorep demonstrate the feasibility of integrating imaging with molecular assays to evaluate safety, delivery efficiency, and antitumor activity. Persisting challenges include limited genome capacity, immune-mediated clearance, and suboptimal signal penetration.</p><p><strong>Conclusion: </strong>Emerging strategies, including synthetic biology reporters, AI-driven image analysis, biosensors, and liquid biopsies, provide scalable, patient-specific tracking solutions. This integrative framework bridges preclinical insights with clinical translation, supporting optimized design, monitoring, and personalization of oncolytic reovirus therapy.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"400-416"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical Study of Radiolabeled LyP-1 for Detecting Sunitinib-induced Changes in the Tumor Microenvironment and Synergistic Antitumor Effects in Triple-negative Breast Cancer.","authors":"Sisi Liao, Qinli Qi, Lifang Jin, Jiali Gong, Lingzhou Zhao, Jinhua Zhao, Meilin Zhu, Ningning Song","doi":"10.1007/s11307-026-02083-y","DOIUrl":"10.1007/s11307-026-02083-y","url":null,"abstract":"<p><strong>Purpose: </strong>Sunitinib is an anti-angiogenic drug that can induce drug resistance characterized by hypoxia. We aimed to synthesize two novel radiolabeled LyP-1 peptides, ^99mTc-HYNIC-LyP-1 and ¹³¹I-LyP-1, to detect sunitinib-induced changes in the tumor microenvironment and improve the therapeutic effects in triple-negative breast cancer (TNBC) mice models.</p><p><strong>Methods: </strong>We synthesized ^99mTc-HYNIC-LyP-1 using hydrazinonicotinamide (HYNIC) as the chelating agent and labeled the LyP-1 peptide with ¹³¹I using the chloramine-T method to synthesize ¹³¹I-LyP-1. Radiochemical purity and stability of the peptides were assessed in vitro using thin-layer chromatography. Tumor accumulation and biodistribution of ^99mTc-HYNIC-LyP-1 were measured in 4T1 xenografts with or without sunitinib treatment. Immunohistochemical analysis was performed to detect sunitinib-induced changes. The therapeutic potential of ¹³¹I-LyP-1 alone and in combination with sunitinib was evaluated in a TNBC mouse model.</p><p><strong>Results: </strong>^99mTc-HYNIC-LyP-1 and ¹³¹I-LyP-1 could be readily prepared with satisfactory labeling efficiency (95.4% ± 0.6% and 72.5% ± 4.5%, respectively) and stability (both more than 90%) in vitro. Micro-single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of mice transplanted with 4T1 tumors using ^99mTc-HYNIC-LyP-1 demonstrated that the uptake of this probe was high in 4T1 xenografts treated with sunitinib at 90 min, whereas it was mild in the control group. Semiquantitative analysis of the ratio of radioactivity intensity at tumor site to that of adjacent muscles (T/M value) showed that the average T/M value of the sunitinib treatment group at 90 min was 3.27, while it was 0.91 in the control group (p = 0.0022). ¹³¹I-LyP-1 could significantly inhibited tumor growth with good organ compatibility and had a synergistic therapeutic effect when combined with sunitinib, with an approximately threefold reduction in the tumor volume in comparison with the control group CONCLUSION: Micro-SPECT/CT imaging using ^99mTc-HYNIC-LyP-1 can be used to monitor sunitinib-induced changes in the TNBC tumor microenvironment. The combination of ¹³¹I-LyP-1 and sunitinib may serve as a novel treatment for TNBC.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"539-551"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accurate Reference Region Calculation in Mouse Brain [¹⁸F]fallypride Studies.","authors":"Alan Miranda, Filipe Elvas, Steven Staelens","doi":"10.1007/s11307-026-02102-y","DOIUrl":"10.1007/s11307-026-02102-y","url":null,"abstract":"<p><p>Quantification of the dopamine D_2/3 receptors tracer [¹⁸F]fallypride is usually performed by defining the cerebellum (CB) as the reference region for its use in kinetic modeling. In mouse studies, [¹⁸F]fallypride is defluorinated causing gradual uptake in the skull which, in addition to extra-striatal binding, can contaminate the CB activity, therefore introducing errors in reference region kinetic modeling. Here we propose a method using non-negative matrix factorization (NMF) to accurately extract the reference region time activity curve (TAC) unaffected by spill-over from surrounding regions. We compared the NMF method with template-based CB reference region (erodedCB), where the region was eroded to avoid spill-over. The different methods were applied in a drug challenge study using RX821002, and compared with results obtained using [¹¹C]raclopride. Striatal and brain parametric maps of nondisplaceable binding potential (BP_ND) were calculated with the different methods, and differences between baseline and challenge were investigated. The NMF reference region TACs showed higher peak and lower tail activity compared with erodedCB. Striatal BP_ND values calculated with NMF were about 20% higher compared to those calculated with erodedCB, and difference between baseline and challenge increased using NMF (NMF: 11.5%, erodedCB: 7.0%). Parametric t-statistic maps show clusters with significant differences using NMF but not with erodedCB. [¹¹C]raclopride BP_ND differences between baseline and challenge were lower (6.1%) than with [¹⁸F]fallypride, but BP_ND variability was lower. In summary, NMF allowed us to extract reference region TACs without contamination from skull or extra-striatal uptake, which improved voxel-wise detection of differences in a drug challenge study.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"490-501"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147729427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in the Development of CRISPR-Based Live-Cell Molecular Imaging and Sensing.","authors":"Min Hou, Yulin Li, Xiaobo Wu, Die Long, Di Sun, Peizhen Chen, Haowei Huang","doi":"10.1007/s11307-026-02110-y","DOIUrl":"10.1007/s11307-026-02110-y","url":null,"abstract":"<p><p>Visualizing genome organization and transcriptional dynamics with spatial and temporal precision in living cells is essential for elucidating gene regulation and chromatin-associated disease mechanisms, yet conventional methods confront a fundamental tension between endogenous-sequence targeting and live-cell compatibility. Operator-repressor systems require prior insertion of repetitive arrays at engineered loci, whereas fluorescence in situ hybridization mandates cell fixation and thereby precludes temporal analysis. CRISPR-Cas technologies, originally developed for genome editing, have been re-engineered into a versatile molecular-imaging toolkit capable of interrogating native sequences in living cells. Here, we systematically review CRISPR-based live-cell imaging and sensing platforms, critically evaluating their design principles, mechanistic foundations, and performance limitations. We examine dCas9-based DNA labeling, dCas12a systems for non-repetitive loci, Cas13- and Csm-mediated RNA imaging, novel fluorescent reporters, engineered ribonucleoproteins, and delivery innovations including reagent-based Oligo-LiveFISH. To organize this diverse literature, we distinguish three operationally distinct modalities-live-cell imaging, intracellular sensing, and diagnostic biosensing-and assess each platform through three unifying design trade-offs: sensitivity versus cellular perturbation, multiplexing capacity versus system complexity, and detection threshold versus biological fidelity. Building on this framework, we evaluate the integration of CRISPR imaging with super-resolution microscopy, artificial-intelligence-driven computational analysis, and multimodal spatial omics. Collectively, this synthesis clarifies current capabilities, delineates unresolved constraints, and charts a coherent path toward clinically relevant applications of CRISPR-based live-cell molecular imaging.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"417-437"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Effectiveness of miR-760 to Distinguish Benign and Malignant Pulmonary Nodules on the Basis of Low-Dose Spiral CT Imaging.","authors":"Jianwen Chen, Fei Li, Jianguang Chen, Quanxing Li, Yujie Ren, Ruibao Liu","doi":"10.1007/s11307-026-02100-0","DOIUrl":"10.1007/s11307-026-02100-0","url":null,"abstract":"<p><strong>Background: </strong>The differential diagnosis of benign and malignant pulmonary nodules is a key problem in clinical diagnosis. Low-dose spiral CT (LDCT) is a commonly used screening method, but it has the limitations of insufficient specificity. There is an urgent need for molecular markers to assist diagnosis.</p><p><strong>Methods: </strong>A total of 240 patients with pulmonary nodules were enrolled in this study. The expression of serum miR-760 was detected by polymerase chain reaction (PCR). Receiver operating curve (ROC) was used to evaluate the potential of miR-760 in the diagnosis of lung cancer, and logistic regression analysis was used to evaluate its significance in the risk assessment of lung cancer. Target genes were screened by bioinformatics, protein-protein interaction (PPI) network was constructed, and hub genes were screened.</p><p><strong>Results: </strong>The expression of miR-760 in the lung cancer group was significantly lower than that in the benign group (P < 0.001). Its AUC for differentiating benign and malignant was 0.867. When LDCT combined with miR-760, the area under the curve (AUC) increased to 0.955. Logistic regression analysis showed that miR-760 was a risk factor for lung cancer incidence. PPI network analysis screened 10 hub genes (HMGCR, INSR, CDK6, etc.), which were enriched in cancer related pathways such as HIF-1 and actin cytoskeleton.</p><p><strong>Conclusions: </strong>miR-760 combined with LDCT can significantly improve the differentiation ability of benign and malignant pulmonary nodules, and its mechanism may activate tumor-related signaling pathways by targeting the core genes of PPI network. This study provides a new combination of molecular markers and mechanistic clues for the accurate diagnosis of pulmonary nodules.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"552-560"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13337837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transporter-Mediated Hepatic Uptake of EOB-DTPA and BOPTA Is Largely Independent of Chelated Metal.","authors":"Legend E Kenney, Christiane L Mallett, Jeremy M-L Hix, Tapas Bhattacharyya, Erik M Shapiro","doi":"10.1007/s11307-026-02105-9","DOIUrl":"10.1007/s11307-026-02105-9","url":null,"abstract":"<p><strong>Purpose: </strong>Metal chelates play a crucial role in diagnostic imaging and radiotherapy. While gadolinium-based chelates are widely used in MRI, radiometal chelates are increasingly used in nuclear medicine and theranostics. Despite their clinical importance, the extent to which the identity of the coordinated metal influences in vivo chelate pharmacology remains unclear. The goal of this work was to determine whether metal substitution alters transporter-mediated cellular uptake and pharmacological behavior of hepatospecific chelates.</p><p><strong>Procedures: </strong>Apo-forms of the clinical hepatospecific MRI contrast agents EOB-DTPA and BOPTA were generated and re-chelated with eight different metals (Sc, Y, Pr, Eu, Gd, Tb, Dy, Ho). In vitro transport of these chelates was assessed in cells expressing rodent and human hepatic transporters. In vivo hepatic uptake was evaluated in mice expressing either wild-type or human hepatic transporters. Tissue distribution and clearance were quantified analytically.</p><p><strong>Results: </strong>In vitro uptake of EOB-DTPA and BOPTA chelates by cells expressing rodent and human transporters showed no statistically significant differences across metals. In vivo studies in mice similarly showed no statistically significant differences in hepatic uptake across metals, with the exception of reduced uptake observed for Sc-EOB-DTPA in wild-type animals. No evidence of free metal accumulation in soft tissue was detected. Chelate clearance via renal and hepatobiliary pathways was similar across metals.</p><p><strong>Conclusions: </strong>Within the class of trivalent metals examined and for EOB-DTPA and BOPTA chelates, transporter-mediated uptake, biodistribution, and clearance were largely independent of metal identity under the conditions tested. These findings support the use of common chelate scaffolds across multiple metals, while highlighting the importance of ligand structure and transporter interactions in governing pharmacology.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"393-399"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13337574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Pilot Study of ¹¹C-acetate and ¹⁸F-FDG with PET/CT and PET/MRI for Lesion Detection in Multiple Myeloma.","authors":"Kristina Yancey, Will Han, Ming Yang, Ba D Nguyen, Nan Zhang, Kristin Graf, Kevin G Shim, Erin E Wiedmeier-Nutor, Udit Yadav, Keith Stewart, Saurabh Chhabra, Leif Bergsagel, Mary Ellen Koran, Felipe Martinez, Steve Huang, Michael Roarke, Rafael Fonseca, Clifford H Shin","doi":"10.1007/s11307-026-02099-4","DOIUrl":"10.1007/s11307-026-02099-4","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the diagnostic performance of ¹¹C-acetate and ¹⁸F-FDG across hybrid PET/CT and PET/MRI platforms in patients with multiple myeloma (MM).</p><p><strong>Methods: </strong>In this prospective pilot study, seven patients with MM underwent repeated-measures imaging with ¹⁸F-FDG PET/CT, ¹⁸F-FDG PET/MRI, ¹¹C-acetate PET/CT, and ¹¹C-acetate PET/MRI. In addition to lesion quantification, the lesions were visually scored for conspicuity. No functional sequences or contrast-enhancement was used in the MRI protocol.</p><p><strong>Results: </strong>¹¹C-acetate detected a greater number of lesions and demonstrated higher visual conspicuity than ¹⁸F-FDG across both PET/CT and PET/MRI platforms.</p><p><strong>Conclusion: </strong>¹¹C-acetate PET imaging may offer improved lesion detection compared to ¹⁸F-FDG in MM. Although the advantage of PET/MRI was not observed over PET/CT in this context, further studies incorporating additional MRI sequences and larger cohorts are warranted.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"523-530"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Imaging of Butyrylcholinesterase Associated with Amyloid-β Plaques Distinguishes 5XFAD from Wild-Type Mice: A Proof-of-Concept.","authors":"G Andrew Reid, Drew R DeBay, Ian R Macdonald, Antoun Bou Laouz, Ian R Pottie, Sultan Darvesh","doi":"10.1007/s11307-026-02107-7","DOIUrl":"https://doi.org/10.1007/s11307-026-02107-7","url":null,"abstract":"<p><strong>Purpose: </strong>Diagnosis of Alzheimer's disease (AD) requires symptoms of dementia and accumulation of amyloid-β (Aβ) and tau in the brain. Molecular imaging of Aβ or tau in AD, though informative, is complicated by the finding that similar changes are found in brains of ~ 30% of cognitively normal older individuals. Butyrylcholinesterase (BChE), normally present in low levels in the cerebral cortex, is found in high levels associated with Aβ plaques in AD. When associated with plaques, the biochemical properties of BChE are altered. The aim of the present study was to determine if the BChE ligand, [¹⁸F]1-methyl-4-piperidinyl p-fluorobenzoate ([¹⁸F]BMP), can image BChE-associated plaques in the 5XFAD mouse model of AD and distinguish it from its wild-type (WT) counterpart.</p><p><strong>Procedures: </strong>[¹⁸F]BMP was synthesized and evaluated in wild-type (WT), 5XFAD and BChE knock-out (BChE-KO) mouse models for in vivo dynamic PET imaging of BChE. Time-activity curves were generated and [¹⁸F]BMP clearance parameters were determined. Brain, liver and urine homogenates were evaluated for [¹⁸F]BMP and its metabolites. Ex vivo autoradiography mapped the distribution of [¹⁸F]BMP brain retention.</p><p><strong>Results: </strong>In vivo PET imaging following injection of [¹⁸F]BMP demonstrated significantly greater brain retention of activity in 5XFAD mice compared to WT, while BChE-KO mice appeared similar to WT levels. Metabolite analysis confirmed [¹⁸F]BMP was metabolized in the periphery but survived in sufficient quantity to enter the brain. Ex vivo autoradiography showed [¹⁸F]BMP retention in the 5XFAD brain where BChE-associated plaques were prominent.</p><p><strong>Conclusions: </strong>These results demonstrate that PET imaging of BChE-associated plaques is feasible, offering an avenue to evaluate the role(s) of BChE in AD pathogenesis and progression to complement the existing AD biomarker framework.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Amyloid Deposition Is Negatively Associated with Cardiac Amyloid Retention in Apo E4 Carriers: A Pilot Study.","authors":"Kyoungjune Pak, Jihyun Kim, Keunyoung Kim, Kyungwon Kim, Yoo Jun Kim, Hyunji Lee, Hwagyu Suh, Eunsoo Moon, Byung-Dae Lee, Je-Min Park, Jung Hyun Choi, Young-Min Lee","doi":"10.1007/s11307-026-02108-6","DOIUrl":"https://doi.org/10.1007/s11307-026-02108-6","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated the relationship between amyloid deposition in the brain and heart using positron emission tomography (PET) scan with a focus on the influence of the apolipoprotein (Apo) E4 genotype.</p><p><strong>Procedure: </strong>Twenty-eight participants (12 healthy controls, 11 patients with mild cognitive impairment, and 5 patients with Alzheimer's disease) were recruited. Each subject visited the institution three times on separate days for echocardiography, brain and cardiac ¹⁸F-Florbetaben PET, and brain magnetic resonance imaging. Myocardial tracer retention (MTR, %) was calculated as the change in the myocardial mean standardized uptake value on summed-frame images of the first 5 min and between 15 and 20 min. Brain amyloid deposition was quantified using the Centiloid scale.</p><p><strong>Results: </strong>The mean MTR of all participants was 24.0%, with no significant difference between Apo E4 carriers and non-carriers. Within this pilot study, an inverse association was identified between MTR and brain amyloid deposition on the Centiloid scale specifically among Apo E4 carriers. In contrast, no significant association was found in Apo E4 non-carriers, consistent with the findings from the full-volume analysis.</p><p><strong>Conclusion: </strong>In this pilot study, an inverse association was observed between brain amyloid β deposition and cardiac amyloid retention in Apo E4 carriers, but not in non-carriers. These findings represent an exploratory clinical observation regarding potential genotype-specific patterns in central and peripheral amyloid dynamics. While the results are hypothesis-generating, they highlight the need for further research into the brain-heart axis in amyloid-related diseases, particularly in genetically at-risk individuals using larger confirmatory cohorts.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of [¹⁸F]FDG and [¹⁸F]PSMA-1007 PET/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study.","authors":"Natália Dalsenter Avilez, Ricardo N Tineo, Juliano Tomé Rodrigues, Arthur Degani Ottaiano, Helena P A Saito, Bárbara Juarez Amorim, José Barreto Campello Carvalheira, Leonardo O Reis, Celso Dario Ramos","doi":"10.1007/s11307-026-02085-w","DOIUrl":"10.1007/s11307-026-02085-w","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the diagnostic performance of [¹⁸F]FDG and [¹⁸F]PSMA‑1007 PET/CT for detecting primary tumors, regional lymph node involvement, and distant metastases in recently diagnosed muscle‑invasive bladder cancer (MIBC).</p><p><strong>Methods: </strong>Prospective single‑center cohort of six patients (ages 57-82). Both PET/CTs were acquired within 30 days under EANM/SNMMI-conformant protocols, with blinded consensus readings and post-diuretic pelvic acquisitions.</p><p><strong>Results: </strong>[¹⁸F]PSMA‑1007 identified 15 lesions versus 14 with [¹⁸F]FDG. Primary bladder lesions were detected in 5 of 6 patients, compared to 3 of 6 patients. Both tracers detected nodal metastases in three patients and bone metastases in one. An [¹⁸F]FDG‑avid pulmonary lesion near the spleen was not detected with [¹⁸F]PSMA‑1007 owing to physiological splenic uptake.</p><p><strong>Conclusion: </strong>Both tracers showed comparable sensitivity for metastatic disease. The hepatobiliary clearance of [¹⁸F]PSMA‑1007 improved visualization of intravesical disease, supporting its use in staging and potential theranostic strategies in selected MIBC patients. Such real-world findings inform refinements for future study procedures, logistics, and methodological design, which are essential for minimizing research waste by identifying potential problems early.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"269-279"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13160961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}